BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 35705560)

  • 21. PD-1, PD-L1, IDO, CD70 and microsatellite instability as potential targets to prevent immune evasion in sarcomas.
    Siozopoulou V; Smits E; Zwaenepoel K; Liu J; Pouliakis A; Pauwels PA; Marcq E
    Immunotherapy; 2023 Oct; 15(15):1257-1273. PubMed ID: 37661910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden.
    Raj SKS; Routh ED; Chou JW; Votanopoulos KI; Triozzi PL; Miller LD
    Cancer; 2022 Sep; 128(17):3254-3264. PubMed ID: 35767280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sarcoma treatment in the era of molecular medicine.
    Grünewald TG; Alonso M; Avnet S; Banito A; Burdach S; Cidre-Aranaz F; Di Pompo G; Distel M; Dorado-Garcia H; Garcia-Castro J; González-González L; Grigoriadis AE; Kasan M; Koelsche C; Krumbholz M; Lecanda F; Lemma S; Longo DL; Madrigal-Esquivel C; Morales-Molina Á; Musa J; Ohmura S; Ory B; Pereira-Silva M; Perut F; Rodriguez R; Seeling C; Al Shaaili N; Shaabani S; Shiavone K; Sinha S; Tomazou EM; Trautmann M; Vela M; Versleijen-Jonkers YM; Visgauss J; Zalacain M; Schober SJ; Lissat A; English WR; Baldini N; Heymann D
    EMBO Mol Med; 2020 Nov; 12(11):e11131. PubMed ID: 33047515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Landscape of Alterations from 1407 Ultra-Rare Sarcomas from the AACR GENIE Database: Clinical Implications.
    Denu RA; Moyers JT; Gouda MA; Conley AP; Lazar AJ; Subbiah V
    Clin Cancer Res; 2023 Nov; 29(22):4669-4678. PubMed ID: 37643131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma.
    Massoth LR; Hung YP; Ferry JA; Hasserjian RP; Nardi V; Nielsen GP; Sadigh S; Venkataraman V; Selig M; Friedmann AM; Samore W; Killian JK; Milante R; Giessinger J; Foley-Peres K; Marcus C; Severson E; Duncan D; Sivakumar S; Ross JS; Desphande V; Ramkissoon SH; Vergilio JA; Louissaint A; Zukerberg LR; Williams EA
    Oncologist; 2021 Jul; 26(7):e1263-e1272. PubMed ID: 33904632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.
    Koelsche C; Renner M; Hartmann W; Brandt R; Lehner B; Waldburger N; Alldinger I; Schmitt T; Egerer G; Penzel R; Wardelmann E; Schirmacher P; von Deimling A; Mechtersheimer G
    J Exp Clin Cancer Res; 2014 Apr; 33(1):33. PubMed ID: 24726063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changing concepts in the pathological basis of soft tissue and bone sarcoma treatment.
    Hogendoorn PC; Collin F; Daugaard S; Dei Tos AP; Fisher C; Schneider U; Sciot R;
    Eur J Cancer; 2004 Jul; 40(11):1644-54. PubMed ID: 15251152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging predictive biomarkers in the management of bone and soft tissue sarcomas.
    Haddox CL; Riedel RF
    Expert Rev Anticancer Ther; 2023 May; 23(5):495-502. PubMed ID: 37017995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel fusion sarcomas including targetable NTRK and ALK.
    Chen T; Wang Y; Goetz L; Corey Z; Dougher MC; Smith JD; Fox EJ; Freiberg AS; Flemming D; Fanburg-Smith JC
    Ann Diagn Pathol; 2021 Oct; 54():151800. PubMed ID: 34464935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrated molecular characterization of adult soft tissue sarcoma for therapeutic targets.
    Kim J; Kim JH; Kang HG; Park SY; Yu JY; Lee EY; Oh SE; Kim YH; Yun T; Park C; Cho SY; You HJ
    BMC Med Genet; 2018 Dec; 19(Suppl 1):216. PubMed ID: 30598078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas.
    Mousses S; McAuley L; Bell RS; Kandel R; Andrulis IL
    Mod Pathol; 1996 Jan; 9(1):1-6. PubMed ID: 8821948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disruption of mammalian SWI/SNF and polycomb complexes in human sarcomas: mechanisms and therapeutic opportunities.
    McBride MJ; Kadoch C
    J Pathol; 2018 Apr; 244(5):638-649. PubMed ID: 29359803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic and molecular abnormalities in tumors of the bone and soft tissues.
    Letson GD; Muro-Cacho CA
    Cancer Control; 2001; 8(3):239-51. PubMed ID: 11378650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole-Genome Sequencing Reveals Mutational Signatures Related to Radiation-Induced Sarcomas and DNA-Damage-Repair Pathways.
    Kim E; Han DJ; Kim BH; Yoo J; Kim HJ; Wu HG; Kim KS; Kim HS; Han I; Moon KC; Park JH; Song S; Kim TM; Chang JH
    Mod Pathol; 2023 Jan; 36(1):100004. PubMed ID: 36788076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma.
    Planas-Paz L; Pliego-Mendieta A; Hagedorn C; Aguilera-Garcia D; Haberecker M; Arnold F; Herzog M; Bankel L; Guggenberger R; Steiner S; Chen Y; Kahraman A; Zoche M; Rubin MA; Moch H; Britschgi C; Pauli C
    EMBO Mol Med; 2023 Apr; 15(4):e16863. PubMed ID: 36779660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sarcomas of Soft Tissue and Bone.
    Ferrari A; Dirksen U; Bielack S
    Prog Tumor Res; 2016; 43():128-41. PubMed ID: 27595362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CORR Insights®: Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
    Iwata S
    Clin Orthop Relat Res; 2024 Mar; 482(3):564-565. PubMed ID: 38289700
    [No Abstract]   [Full Text] [Related]  

  • 39. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
    Sethi TK; Keedy VL
    Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review.
    Andritsch E; Beishon M; Bielack S; Bonvalot S; Casali P; Crul M; Delgado Bolton R; Donati DM; Douis H; Haas R; Hogendoorn P; Kozhaeva O; Lavender V; Lovey J; Negrouk A; Pereira P; Roca P; de Lempdes GR; Saarto T; van Berck B; Vassal G; Wartenberg M; Yared W; Costa A; Naredi P
    Crit Rev Oncol Hematol; 2017 Feb; 110():94-105. PubMed ID: 28109409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.